SRR493951
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 44
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03093 | — | cohortA1 | 0.875 |
| 2 | TCGA-AR-A0TT-01A-31R-A084-07 | — | D | 0.863 |
| 3 | C3L-04071 | — | cohortSQ1 | 0.842 |
| 4 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.831 |
| 5 | TCGA-55-A493-01A-11R-A24H-07 | — | cohortA1 | 0.816 |
| 6 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.816 |
| 7 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.816 |
| 8 | C3N-02152 | — | cohortA1 | 0.814 |
| 9 | BS_Z8F3GM85 | high-grade glioma | — | 0.813 |
| 10 | TCGA-AR-A1AJ-01A-21R-A12P-07 | — | D | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |